SUBSCRIBERS

Roche drug cocktail doubles chance of holding lung cancer at bay

Fri, Dec 08, 2017 - 5:50 AM

Zurich

ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.

Thirty-seven per cent of patients in a closely watched clinical...

To continue reading

for full content

if you are a subscriber

Get our introductory offer at only

$0 .99*/month

Cancel anytime

*$0.99/month for first 3 months

$29.90/month for the next 9 months

Need help?

CALL +65 6388 3838 EMAIL btocs@sph.com.sg

OPERATING HOURS (+8 GMT) MON-FRI: 8:30AM-5:30PM

Register to read this article. Log in if you are already a subscriber. Register to read this article. Log in if you are already a subscriber. Please log in or subscribe to continue reading.